---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-309716"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:16:24.382082+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GSK terminates collaboration; IDEAYA regains IDE275 and IDE705; cash runway unchanged

## Summary
- GSK terminates Collaboration, Option and License Agreement effective 90 days after Dec 4, 2025; programs transferred back to IDEAYA.
- IDEAYA to evaluate strategic options for IDE275 (Werner Helicase) and IDE705 (Pol Theta) in 2026.
- Company reaffirms cash runway into 2030, unchanged by the termination.

## SEC filing metadata
- accession: 0001193125-25-309716
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312525309716/0001193125-25-309716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312525309716/d87387d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-309716
- JSON: https://secwatch.observer/filing/0001193125-25-309716.json
- Plain text: https://secwatch.observer/filing/0001193125-25-309716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.